Exousia Bio, Inc.
Datakwaliteit: 100%
LMMY
OTC
Services
Educational Services
€ 0,30
▼
€ 0,10
(-25,00%)
Marktkapitalisatie: 22,05 M
Prijs
€ 0,30
Marktkapitalisatie
22,05 M
Dagbereik
€ 0,26 — € 0,30
52-Weeksbereik
€ 0,06 — € 16,00
Volume
5.000
Openen € 0,26
50D / 200D Gem.
€ 0,39
22,76% below
50D / 200D Gem.
€ 0,32
7,24% below
Quick Summary
Belangrijkste Punten
Earnings declined -150,21% over the past year
ROE of 0,13% is below average
Net margin of 399,42% shows strong profitability
Generating 183.169,0 in free cash flow
P/E of 1522,90 — premium valuation
Cash machine — converts 1265,07% of earnings into free cash flow
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)206,67%
Earnings (1Y)-150,21%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
0,13%
Boven sectorgemiddelde (-15,95%)
ROICN/A
Net Margin399,42%
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,00
Interest CoverageN/A
Waardering
PE (TTM)
1522,90
Boven sectorgemiddelde (-1,17)
P/B Ratio1,01
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Services sector mediaan (502 peers)
Sectorvergelijking
vs Services sector mediaan (502 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 1522,9 | -1,2 |
| P/B | 1,0 | 1,4 |
| ROE % | 0,1 | -16,0 |
| Net Margin % | 399,4 | -19,4 |
| Rev Growth 5Y % | — | 4,0 |
| D/E | — | 0,4 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 206,67% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | -150,21% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 3.625,0 | Net Income (TTM) | 14.479,0 |
| ROE | 0,13% | ROA | 0,13% |
| Gross Margin | -1880,00% | Operating Margin | N/A |
| Net Margin | 399,42% | Free Cash Flow (TTM) | 183.169,0 |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,00 |
| Interest Coverage | N/A | Asset Turnover | 0,00 |
| Working Capital | -261.023 | Tangible Book Value | 21,79 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 1522,90 | Forward P/E | N/A |
| P/B Ratio | 1,01 | P/S Ratio | 6082,76 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 0,83% | ||
| Market Cap | 22,05 M | Enterprise Value | 22,05 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,00 | Revenue / Share | 0,00 |
| FCF / Share | 0,00 | OCF / Share | 0,00 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 1265,07% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2025 | FY2023 |
|---|---|---|---|
| Revenue | 11.500,0 | 3.750,0 | 0,0 |
| Net Income | -25.807,0 | 51.395,0 | -56.421,0 |
| EPS (Diluted) | 0,00 | 0,00 | 0,00 |
| Gross Profit | 1.833,0 | -3.501,0 | 0,0 |
| Operating Income | — | — | -56.421,0 |
| EBITDA | — | — | — |
| R&D Expenses | — | — | — |
| SG&A Expenses | — | — | — |
| D&A | — | — | — |
| Interest Expense | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2025 | FY2023 |
|---|---|---|---|
| Total Assets | 27.453,0 | 0,0 | 37.044,0 |
| Total Liabilities | 82.348,0 | 0,0 | 66.132,0 |
| Shareholders' Equity | -54.895,0 | 0,0 | -29.088,0 |
| Total Debt | — | — | — |
| Cash & Equivalents | — | — | 7.855,0 |
| Current Assets | 12.964,0 | 0,0 | 7.855,0 |
| Current Liabilities | 14.169,0 | 0,0 | 3.610,0 |
{"event":"ticker_viewed","properties":{"ticker":"LMMY","listing_kind":"stock","pathname":"/stocks/lmmy","exchange":"OTC","country":"US"}}